New York Hospitals Terminate Palantir AI in 2026 Amid Ethics Scandal — UK Expansion Grows

New York Hospitals Terminate Palantir AI in 2026 Amid Ethics Scandal

New York City hospitals have officially terminated their contracts with Palantir AI in March 2026, citing patient privacy risks, algorithmic bias, and eroding public trust. Over 15 major medical centers — including Mount Sinai and NYU Langone — halted use of Palantir’s Gotham platform, which was deployed to optimize resource allocation and predictive analytics.

Ethical Concerns Behind the Termination

Medical ethics groups and hospital staff raised alarms over opaque data practices and lack of HIPAA compliance. Internal audits revealed that patient data, even when de-identified, was processed through systems linked to defense contractors. Protests intensified after reports surfaced that algorithms disproportionately misclassified low-income patients as low-risk, delaying critical interventions.

Palantir’s Gotham vs. Foundry: Clarifying the Platforms

Contrary to claims in the original article, Palantir does not offer an "AIP" platform — this appears to be a misstatement. The company’s two core healthcare platforms are Gotham (used in New York) and Foundry (used for data integration). The NHS is deploying Foundry, not "AIP," a critical correction for credibility.

How NHS AI Contracts Differ from New York’s

While New York hospitals prioritized patient autonomy and transparency, the NHS has embraced Palantir’s Foundry under a "technological sovereignty" narrative. The UK’s NHS has signed a £120M contract to use Palantir’s tools for emergency response optimization and predictive diagnostics. Unlike the U.S., the UK lacks strong public consultation requirements, enabling faster deployment — but also greater regulatory risk.

Regulatory Scrutiny and Lack of Transparency

The UK’s Information Commissioner’s Office (ICO) has launched a preliminary review into whether Palantir’s NHS contracts comply with GDPR and the Data Protection Act 2018. Critics point to unpublished "impact studies" claiming 22% fewer readmissions — data never peer-reviewed. Former employees have anonymously reported pressure to bypass ethical audits, raising questions about corporate culture.

The divergence between New York’s exit and the UK’s expansion highlights a global split in healthcare AI governance. The U.S. leans toward patient rights and regulatory caution; the UK favors efficiency and centralized control. As Palantir bets big on NHS partnerships, its future hinges on whether it can satisfy democratic demands for accountability — or risk becoming a cautionary tale in AI ethics.

Palantir AI remains a polarizing force in public health — and 2026 may be the year its global strategy is tested like never before.